Hu14.18-IL-2 is an immunocytokine (IC) fusion protein consisting of a humanized anti-disialoganglioside (GD2) monoclonal antibody and human recombinant IL-2 (hrIL-2) developed to exert superior anti-tumor activity against melanoma and neuroblastoma. The gene discussed is IL2; the disease is melanoma.